Chronic hepatitis B infection remains a serious global health threat, contributing to a large
number of deaths through liver cirrhosis and hepatocellular carcinoma. Current treatment …

Highlights•Prophylactic vaccines work well, but we still lack a successful therapeutic vaccine
able to break immune tolerance in chronic infection or cancer.•Chronic hepatitis B is …

More than 250 million people worldwide are chronically infected with hepatitis B virus
(CHB), and over half a million die each year due to CHB-associated liver complications such …

The treatment of chronic hepatitis B virus (HBV) infection has greatly improved over the last
10years, but alternative treatments are still needed. Therapeutic vaccination is a promising …

Chronic liver disease and hepatocellular carcinoma due to chronic hepatitis B virus (HBV)
infection pose a major public health problem in highly endemic regions. Effective vaccines …

Despite effective prophylactic vaccines against hepatitis B virus existing for over 20 years,
more than 2.5 billion people worldwide have been exposed to the disease and …

The currently used nucleoside analogs (ie entecavir and tenofovir) with high barrier-to-
resistance efficiently suppress viral replication, limit inflammation and reduce the sequelae …

Therapeutic vaccination for the treatment of chronic hepatitis B has so far shown limited
clinical efficacy. In this review, we argue that the principal cause of this failure is the …

Chronic liver disease and hepatocellular carcinoma associated with chronic hepatitis B virus
(HBV)-infection are among the most serious human health problems in highly endemic …

World Health Organization (WHO) estimates that 257 million people were living with chronic
hepatitis B virus (HBV) infection. Highest HBV prevalence was found in the WHO Western …